Jochen Dick, who has led the integration process into the azbil Group as CEO of the company since 2017, will keep his role as non-executive Vice Chairman of the Board of Directors of Azbil Telstar.
After a 10-year transformation process from the integration of Telstar into the azbil Group, the management of the company at the highest-level will be transferred to two internal executives.
Azbil Telstar has announced the appointment of Jordi Puig as a Chief Executive Officer (CEO) and Emili Pablos as Executive Vice President & Chief Financial Officer (CFO) of the company. Jochen Dick, currently CEO of the company, will focus on his role of non-executive Vice Chairman of the Board of Directors of Azbil Telstar. Both appointments, which are effective on 31st July 2023, have been carried out after a transformation process from the integration of Telstar into the azbil Group. The appointment of Jordi Puig and Emili Pablos as Managing Directors of Azbil Telstar in April 2022 marked the beginning of the transition process towards a new structure of corporate governance and internal executive management of the business.
The decision has been taken after evaluating the positive impact of Telstar’s transformation process on its integration into the corporate governance structure of the azbil Group since 2013, when Telstar moved from a family-owned structure to a corporate governance structure of a listed company. This process has been led by Jochen Dick since 2017 to reinforce the company’s global strategic position and guarantee long-term sustainable growth.
After the acquisition process carried out by azbil Group in 2013, Azbil Telstar has been leading the Life Science Engineering business division of the Japanese corporation to provide global high-technology solutions in design, engineering, and manufacturing processes with automation technologies for the international life science markets. Throughout ten years of an evolution process of integration, the Telstar brand has consolidated its well-known reputation being acknowledged as one of the 10 major international innovative suppliers for the pharmaceutical industry, operating in over a hundred countries through its 11 subsidiaries around the world.